-
Bristol-Myers Squibb Co. et al v. Mylan Pharmaceuticals Inc. et al DC CAFC
- 1:09-cv-00651
- D. Del.
- Judge: Leonard P. Stark
- Filed: 08/28/2009
- Closed: 11/05/2013
- Latest Docket Entry: 12/30/2014
- PACER
2
Plaintiffs
3
Defendants
2
Accused
Products
1
Patent-in-Suit
1,531
Days in
Litigation
-
Bristol-Myers Squibb Co. et al v. Mylan Pharmaceuticals Inc. et al DC CAFC
- 1:09-cv-00651
- D. Del.
- Judge: Leonard P. Stark
- Filed: 08/28/2009
- Closed: 11/05/2013
- Latest Docket Entry: 12/30/2014
- PACER
Causes of Action
Infringement
Other
Declaratory Judgment
Patent Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
-
Infringement
Matrix Laboratories Limited
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 600 mg dosage strength of SustivaANDA productCrystalline efavirenzGeneric efavirenz tablets pursuant to ANDA No. 91-471 | US 6,673,372 B1 | All Asserted Claims |
Infringement
Entry 254Entry 243 Entry 236 Entry 238 |
Mylan Pharmaceuticals Incorporated
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 600 mg dosage strength of SustivaANDA productCrystalline efavirenzGeneric efavirenz tablets pursuant to ANDA No. 91-471 | US 6,673,372 B1 | All Asserted Claims |
Infringement
Entry 254Entry 243 Entry 236 Entry 238 |